July 18, 2018
Delegation of Tasks Log (DTL) Components of the Trial Participants ListPublished: July 18, 2018Category: Group updates  The DTL has now been implemented by the Clinical Trials Evaluation Program (CTEP) for selected trials. The first National Clinical Trials Network Trial (NCTN) where CCTG is using the DTL is the BLC.4 trial. An active DTL is now a requirement for CCTG sites following approval of the BLC.4 Revision #3. Other upcoming studies that will be using the DTL initially include MAC.24 and REC.4. Read More |
 The Canadian Cancer Trials Group (CCTG) Operations and Statistical Centre (OSC), based at the Queen’s University Cancer Research Institute in Kingston, Ontario is seeking a physician with hematology or oncology training with demonstrated interest and experience with developing and cancer therapy trials. Senior investigators work at the OSC with members of the investigational new drug and disease-specific and trial endpoint committees, which have national investigator leadership and membership, to develop and implement the CCTG clinical trials research agenda. Read More |
 The results of the Canadian Cancer Trials Group (CCTG) BL.12 phase II randomized trial were presented at ASCO 2018 by Dr. Srikala Sridhar, the BL.12 Study Chair. In this interview Dr. Sridhar discusses the BL.12 study and what is next for bladder cancer clinical trial research. Read More |
July 04, 2018
CCTG Clinical Research Associates Executive Committee – Recruitment of CRA MembersPublished: July 04, 2018Category: Trials  The Canadian Cancer Trials Group is currently seeking additional members for our Clinical Research Associates Executive Committee (CRAEC). Please feel free to distribute this call for volunteers within your clinical trials department, and encourage applications from interested and qualified individuals. Read More |
 Since being diagnosed with multiple myeloma in 2002, Aldo has directed his attention to building an effective national platform to address the needs of the Canadian myeloma community. Aldo founded Myeloma Canada which is the only national non-profit organization uniquely focused on the needs of the Canadian myeloma community. As a patient-driven, grassroots organization, Myeloma Canada’s provides educational resources to patients and advocate for improved access to new therapies and accelerate patient-focused myeloma research. Read More |
 Randomized Phase II Feasibility Trial Of Image Guided External Beam Radiotherapy With Or Without High Dose Rate Brachytherapy Boost In Men With Intermediate-Risk Prostate Cancer
|
June 20, 2018
 The Canadian Cancer Trials Group's (CCTG) Supportive Care (former Symptom Control) Committee (SCC) is currently seeking individuals with interest and experience in supportive care trials to join the SCC Executive. In broad terms (adapted from the CCTG's Terms of Reference) the roles of the Disease Site Committee (DSC) Executive members are to: Read More |
 The Delegation of Tasks Log (DTL) has now been implemented by the Clinical Trials Evaluation Program (CTEP) for selected trials. The first National Clinical Trials Network (NCTN) trial where CCTG will be using the DTL is the BLC.4 trial. An active DTL has been added as a requirement for CCTG sites following approval of the BLC.4 Revision #3. Other studies that will be using the DTL initially include MAC.24 and REC.4. Read More |